Peter Elyanu 1, Addy Kekitiinwa 2,Rousha Li 1, Mary Paul 3, LY Hwang 1

Similar documents
1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London

The Cumulative Incidence of HIV Infection in HIVexposed Infants with a Birth Weight of 1500g Receiving Breast Milk and Daily Nevirapine

TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV

Figure S1: Overview of PMTCT Options A and B. Prevention of Mother to Child HIV Transmission (PMTCT)

DEPARTMENT. Treatment Recommendations for. Pregnant and Breastfeeding Women: Critical Issues Consolidated ARV Guidelines. Dr.

Update on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines

The New National Guidelines. Feeding in the Context of HIV. Dr. Godfrey Esiru; National PMTCT Coordinator

CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010

Monitoring of HIV positive mothers and HIV exposed infants in context of Option B+ implementation

Infertility Treatment and HIV

Dr Graham P Taylor Reader in Communicable Diseases

Uganda. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)

Impact of South Africa s PMTCT Programs on Perinatal HIV Transmission: Results of the 1st Year Implementing 2010 WHO Recommended Guidelines

Mother to Child HIV Transmission

A Descriptive Study of Outcomes of Interventions to Prevent Mother to Child Transmission of HIV in Lusaka, Zambia

Objectives. Outline. Section 1: Interaction between HIV and pregnancy. Effects of HIV on Pregnancy. Section 2: Mother-to-Child-Transmission (MTCT)

treatment during pregnancy and breastfeeding

Research Article Challenges in Assessing Outcomes among Infants of Pregnant HIV-Positive Women Receiving ART in Uganda

DECLINE IN POSITIVITY RATES AMONG HIV-EXPOSED INFANTS WITH CHANGES IN PMTCT ARV REGIMENS IN NIGERIA: EVIDENCE FROM 7 YEARS OF FIELD IMPLEMENTATION

Cote D'Ivoire. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)

Infant feeding and HIV Policy, Evidence and Hospital Challenges

No. individuals current on treatment (ART) - PEPFAR Indicator Reference Sheets

The Global Partnership for HIV-Free Survival (PHFS): Quality Improvement and Breastfeeding / ART compliance

XVII INTERNATIONAL AIDS CONFERENCE MEXICO CITY, 3-8 August 2008 SCALING-UP NATIONAL PMTCT PROGRAM

Dr HM Sebitloane Chief Specialist (Outreach) Dept of O+G NRMSM

targets for HIV-positive children

Mortality risk factors among HIV-exposed infants in rural and urban Cameroon

Infant feeding in the ARV era. Department of Obstetrics and Gynaecology Faculty of Health Sciences and Tygerberg Hospital

Outline. Aim with PMTCT. How are children transmitted. Prevention of mother-to-child transmission of HIV. How does HIV transmit to children?

Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:

Applying Improvement to Keep HIV+ Mothers and Exposed Infants in Care. Anisa Ismail Improvement Advisor University Research Co.

Breast Feeding for Women with HIV?

Impact of Option B on mother-to-child HIV transmission in Rwanda: an interrupted time series analysis

The availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings

6IATT Toolkit, Expanding and Simplifying Treatment for Pregnant Women Living with HIV: Managing the Transition to Option B/B+

The promises & challenges of universal ART for women in southern Africa: Option B+ and beyond. Landon Myer

hiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants

Prevalence of HIV and Associated Factors among Infants Born to HIV Positive Women in Amhara Region, Ethiopia

Botswana. HIV Country Profile: Health expenditure, total (% of GDP) (2016) Total fertility rate (births per woman) ( )

Making infant feeding safer progress and challenges in feeding and infant prophylaxis. Dr Lee Fairlie Priorities 2012

Living Positively with HIV

PMTCT Max Kroon Mowbray Maternity Hospital Division of Neonatal Medicine School of Child and Adolescent Health University of Cape Town

Using new ARVs in pregnancy

Progress & challenges in PMTCT: The unfinished agenda

Eswatini. HIV Country Pro le: Maternal mortality per live births (2015) Health expenditure, total (% of GDP) (2015)

The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT

Paediatric HIV Drug Resistance 26th-International-Workshop-on-HIV-Drug-Resistance-programme [2].tiff

STRATEGIES FOR MATERNO- FETAL TRANSMISSION OF HIV, HIV AND HBV COINFECTIONS IN CONSTANTA - ROMANIA

Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014

All HIV+ Women on Antiretroviral Therapy Should Breastfeed in Both Low and High Resource Settings VOTE NO!!

Evaluation of HIV-1 viral load among mothers under PTMCT program with lymphocytes T CD4 count above 350 cells/µl

Science roadmap on antiretroviral drugs for PMTCT and maternal treatment: current guidance, evidence in development and gaps

HIV Infection in Pregnancy. Francis J. Ndowa WHO RHR/STI

Integrating prevention & management of STI/HIV/AIDS into reproductive, maternal and newborn health services in China

Performance Management Plan Indicator Worksheet #1

PMTCT (getting to zero ) Stepping up the pace and challenges of achieving emtct in low resource settings

HIV. Transmission modes. Transmission modes in children. Prevention of mother-to-child transmission of HIV. HIV identified in 1983

PMTCT UPDATE. AWACC CONFERENCE DURBAN SEPT 2013 Dr HM Sebitloane Chief Specialist, Dept of O+G, NRMSM

Virologic Outcomes of HIV-Infected Children Undergoing a Single-Class Drug Substitution from LPV/r- to EFV-Based cart: A retrospective cohort study.

Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive

Adherence to ART and retention in care among HIV- infected pregnant women starting life-long treatment in. Ifakara, Tanzania.

Scaling up priority HIV/AIDS interventions in the health sector

Using new ARVs in pregnancy

PREVENT TRANSMISSION OF HIV/AIDS PREGNANT WOMEN : LITERATUR REVIEW

IDENTIFYING INTERVENTIONS TO IMPROVE OUTCOMES OF THE SOUTH AFRICAN PREVENTION OF MOTHER-TO-CHILD TRANSMISSION PROGRAMME

Three years Option B+ in Malawi Success and challenges of a novel programme to prevent mother-to-child transmission of HIV

Sierra Leone. HIV Epidemiology Report 2016

HIV AND INFANT FEEDING

Original Research Article. Bhagyalakshmi R. T. 1 *, T. P. Manjunath 1, C. R. Banapurmath 2, Mruthunjaya S. 2

Updates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013

WHO recommendations. Diagnostic testing in infants

QUESTIONS AND ANSWERS

Preliminary Outcomes of the PMTCT Option B+ programme in Thyolo District, Malawi

Measuring Effectiveness of PMTCT Programs

All HIV-exposed Infants Should Receive Triple Drug Antiretroviral Prophylaxis. Against the motion

Early Antenatal (<36 weeks) Late Antenatal (36 weeks to labor) Early Antenatal (<36 weeks) Late Antenatal (36 weeks to labor)

Factors associated with HIV infection despite overall low transmission rates in HIV Exposed Infants in rural Kenya

Challenges of HIV drug resistance in resource-limited settings

The Promise of HIV Prevention in Pregnancy. Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA

The Contribution of Family Planning towards the Prevention of HIV Mother-to-Child Transmission (PMTCT) in Uganda

Fertility desires of pregnant and nonpregnant women before and after availability of PMTCT services in Rakai, Uganda

CHAI Cambodia: HIV Program Update NCHADS Annual Operational Comprehensive Planning Workshop Dec 3, 2012

Influence of Breastfeeding Practices on HIV-1 Susceptible T Cells in HIV-1 Exposed Ugandan Infants. On behalf of the MAMU Team Elizabeth J.

Strengthening the Integration of PMTCT within MNCH Services

UPDATE TRAINING ARV TREATMENT GUIDELINES TRAINERS CASE STUDIES & ANSWER GUIDE

Revisiting Optimal Breast Feeding Durations: Modelling the impact of maternal ARV use and infant mortality

Elijah Paintsil, MD, FAAP

Monitoring, Evaluation, and Reporting (MER) Guidance (v2.3): PMTCT. Presenter: Jenny Albertini, S/GAC Date: October 2018

Lessons learned from past passive immunization trials to prevent HIV MTCT

Phase II clinical trial TEmAA. Didier Koumavi EKOUEVI, MD PhD (Principal Investigator)

Fertility Responses to Prevention of Mother-to-Child Transmission of HIV

Tunisian recommendations on ART : process and results

Delivering care to women and children In low income countries G.Liotta MD, PhD. diseases relief by excellent and advanced means

GLOBAL AIDS MONITORING REPORT

EVIDENCE SUMMARIES OF INDIVIDUAL REPORTS IDENTIFIED THROUGH A SYSTEMATIC REVIEW

Early Antiretroviral Therapy in Newborns: Opportunities and Challenges. Ellen Gould Chadwick MD Northwestern University Feinberg School of Medicine

Prevention of Mother to Child Transmission of HIV: Our Experience in South India

Malaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh

Discontinuation of cart postpartum in a high prevalence district of South Africa in 2014

Transcription:

OUTCOMES OF HIV EXPOSED INFANTS BEFORE AND AFTER IMPLEMENTING OPTION B+ PMTCT GUIDELINE IN KAMPALA,UGANDA: A RETROSPECTIVE COHORT STUDY. Peter Elyanu 1, Addy Kekitiinwa 2,Rousha Li 1, Mary Paul 3, LY Hwang 1 1. University of Texas School of Public Health, Houston, Texas 2. Baylor-Uganda, Kampala, Uganda 3. Baylor College of Medicine, Houston, Texas

Background In 2012, WHO recommended providing lifelong ART to all HIVinfected pregnant and breastfeeding women, and ARV prophylaxis for their infant for six weeks (Option B+) as part of the strategy to eliminate MTCT. Reports show 6 week MTCT rates < 5% (Maria H Kim et al, 2015, Sebastian et at., 2015, Hierce et al 2015, William Bazeyo et al 2015) However, to date the impact of Option B+ guidelines on 18 month outcomes of HEI from programmatic settings is limited. And yet 18 months outcomes measure the success of PMTCT interventions at preventing HIV transmission through breastfeeding, and the impact of child survival intervention.

Objectives 1. To compare HIV exposed infant outcomes (MTCT rate, LTFU and mortality) at 18 months of life, before and after implementing option B+ in Mulago Hospital, Kampala Uganda. 2. To compare cart initiation proportions in Infant who test HIV positive before and after implementing Option B+ in Mulago hospital, Uganda 3. To determine factors associated with MTCT after implementing Option B+ in Mulago hospital, Uganda.

Methods Study Design: Retrospective Cohort study Cohort definition: HIV exposed Infants born from; July 2010-June 2011 (Option A cohort) July 2013 to June 2014 (Option B+ cohort) Excluded those born from July 2011-June 2013 Reduce overlap between the 2 cohorts because of transition of the guidelines Study setting: Mulago Hospital postnatal clinic Data collection: Routinely collected patient-level data from the clinic s electronic database.

Objective 1: To compare HIV exposed infant outcomes (MTCT rate, LTFU and mortality) before and after implementing option B+. Study Population: HEI aged <18 months. Attended the Mulago Hosp PNC clinic at least once after birth Received 1 st HIV test at Mulago Hosp clinic. Excluded: Transferred in s from other clinics. Outcomes variables HIV infection, Loss to Follow up &Death

Outcome definition HIV infection: At least, one positive HIV DNA PCR test anytime during the follow-up period or a positive HIV rapid test at 18 months of age. LTFU: If there were three failed attempts to track the infant after the last clinic visit or if six months elapsed since the infant was last seen at the clinic. HIV Negative: Negative HIV DNA PCR test -done at least six weeks after cessation of breastfeeding or Negative HIV rapid test at 18 months of age. Transfer out: The infant transferred care to another health facility before any of the other events occurred.

Survival analysis Statistical analysis Compared 18 month cumulative incidence estimates of outcomes while accounting for competing risks. Outcome Time of origin Competing risk Censored event HIV infection Date of birth Death HIV negative Transfer out Loss to follow up Loss to follow Up Date of enrolment in care Death HIV infected HIV negative Transfer out Death Date of Birth HIV negative HIV infected Transfer out Loss to follow up

Objective 2: To compare ART initiation proportions of HIV+ Infant before and after implementing Option B+ Study Population: Infants who become HIV infected. We used Fisher s exact test to compare cart initiation proportions in HIV-infected infants in the two cohorts. Objective 3: Determine factors associated MTCT of HIV during Option B+ Proportional subdistribution hazard regression model for competing risks(fine and Gray, 1999) We used stepwise approach to select the most parsimonious model. Variables with p<0.2 at univariable analysis were considered for model selection.

RESULTS Baseline characteristics- Infants Characteristic Option A Cohort N=2203 Option B+ cohort N=1571 Median age in weeks at 1 st PCR (IQR) 6.4(6.1,7.3) 6.3(6.0,6.7) Sex [n (%)] Male 1131 (51.3%) 788(50.2%) Median follow up months(iqr) 9.6(3.1, 16.4) 15.3(4.2, 16.5) Feeding option [n (%)] EBF 1962(89.1%) 1447(92.2%) ARV s for PMTCT [n (%)] Yes 2150(98.3%) 1542(98.5%) PMTCT ARV regimen Daily NVP up to 6 weeks 1113(50.9%) 1529(97.6%) Daily NVP through BF 897(41.0%) 13(0.8%) sd NVP 140(6.4%) 0(0.0%) None 36(1.7%) 24(1.5%) Underweight [N (%)] Yes 214(10%) 197(12.8%) Stunted [N (%)] Yes 162(7.7%) 141(9.6%) 22 (0.6%) Missing values

Mothers characteristics at child s enrolment Characteristic Option A Cohort N=2203 Option B+ cohort N=1571 Mode of delivery [N (%)] Vaginal Delivery 1832(83.2%) 1282(81.6%) Caesarean section 371(16.8%) 289(18.4%) Place of delivery [N (%)] Health facility 2148(98.4%) 1545(98.4%) Home/TBA 34(1.6%) 25(1.6%) ARV s for PMTCT Yes 2118(96.4%) 1517(96.7%) No 79(3.6%) 52(3.3%) PMTCT regimen [N (%)] cart 1074(48.9%) 1508(96.1%) AZT+3TC, sdnvp 361(16.4%) 9(0.6%) AZT, sdnvp 483(22.0%) 0(0%) sdnvp 200(9.1%) 0(0%) None 79(3.6%) 52(3.3%) 22 (0.6%) Missing values; 8 (0.2%)missing values; cart Combination antiretroviral therapy.

18 month cumulative incidence of HIV infection Gray s p-value =0.2 Option A 5.1% (95% CI: 4.3,6.2%) Option B+ 4.3% (95% CI: 3.3,5.5%) 6 wks

18 month cumulative incidence of Loss to follow up Gray s p-value =0.06 Option A 30.3% (95% CI: 28.4,32.3%) Option B+ 28.4% (95%: 26.2,30.7%)

18 month cumulative incidence of mortality Gray s p-value =0.06 Option A 0.9% (95%CI: 0.5,1.5%) Option B+ 1.4% (95%CI: 0.8,2.2%)

Proportion of HIV infected infants initiated on cart before and after Option B+ Characteristic Option A Cohort N=97 Option B+ cohort N=58 p-value Initiated on ART [n (%)] 0.04 Yes 72(74.2%) 51(87.9%) No 25(25.8%) 7(12.1%) Median age at HIV Diagnosis(months) 1.9(1.5,8.4) 3.7(1.5,8.1) 0.35 Median months from HIV diagnosis to cart initiation(iqr) 2.3(1.6,4.2) 0.6(0.4,0.8) <0.01

Factors associated with MTCT of HIV during option B+ Final Model <0.001 Predictors Number %infected Adjusted HR Yes 1517 2.2 Reference Mother ARV s for PMTCT a No 52 46.2 16.3(7.6,34.6) Infant ARV s for PMTCT b Yes 1542 2.8 Reference No 24 14 2.5(1.03,4.95) 0.04 a 2 missing values; b 5 missing values Other variables that were significant at univariable analysis but were eliminated in the final model were; Infant feeding method, age at 1 st PCR, place of delivery

Discussion We observed similar and low cumulative incidence of HIV infection Half of mothers in Option A cohort received cart The findings may be different from what lower level facilities with different implementation challenges may find. CI increased from 1% at 6 wks-4.3% at 18 month. MTCT rates observed at 6wks could double by 18 months(ciaranello et al., 2011, Schmitz et al., 2013) Highlights the need for countries to report both 6 wk. and 18 months MTCT rates. LTFU is high in both cohorts despite robust follow up mechanisms. Referral centre, mother receive care apart from infants and clients may self transfer. Estimates of HIV and Mortality are susceptible to bias due to LTFU Sensitivity analysis: HIV infection Option B+ lower bound: 3.8% upper bound 31% Limitation: We studied infants who came for care after delivery. Our results could under-estimate outcomes.

Conclusion Outcomes of HIV-exposed infants at 18-months of life Pre and post Option B+ were similar; however, the cart initiation in HIV-infected infants was better during B+ implementation. Mothers or infants not receiving ARV s predicted MTCT during Option B+. LTFU remains high and should be addressed.

Acknowledge